Efficacy and safety of the pandemic influenza A(H5N1) vaccination on whether the sequential hetero-strains vaccination would provide wide range of immunogenicity, and whether single-shot vaccination would develop effective priming. - Efficacy and safety of the pandemic influenza A(H5N1) vaccination on sequential heterologous strains administration and single administration for priming (H5N1_VI hetero-sequence and single priming)

Clinical Research Center, National Hospital Organization0 个研究点目标入组 300 人开始时间: 2012年1月10日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Individuals with the history of Swine Influenza A (H5N1) virus infection. (obtained fromsubjects) 2) Individuals, who had history of anaphylaxis to foods or medicines previously. 3) Individuals with severe diseases in cardiovascular, blood, respiratory, liver, kidney, digestive or neurological systems in their clinical recording. 4) Individuals with a history of acute disseminated encephalomyelitis and Guillain-Barre syndrome in the past. 5) Individuals participated in a clinical trial within four months (counted from the date of vaccination). 6) Individuals vaccinated with live vaccine within 27 days, or received a dose of inactivated vaccine within six days (including the day of vaccination). 7) Individuals received with gamma globulin or blood transfusion within three months, or received the formulation of high dose of gamma globulin therapy (200 mg/kg or more) within six months (including the day of vaccination). 8)Individuals who are deemed to be inappropriate by the investigator

发起方

Clinical Research Center, National Hospital Organization